Association Between Risk Factors and Medication Use Among Patients with Polycystic Ovary Syndrome at Kencana Clinic, Sorong City
Article metrics
OJS usage and citation sourcesViews and downloads are recorded by OJS; statistics processing may be delayed. A dash means the source count is unavailable. Search Google Scholar
Article Sidebar
Adriyani E. G. Sitanggang, Lukman Hardia, Irwandi (2026). Association Between Risk Factors and Medication Use Among Patients with Polycystic Ovary Syndrome at Kencana Clinic, Sorong City. Journal of Pharmaceutical and Sciences, JPS Volume 9 Nomor 3 (2026). https://doi.org/10.36490/journal-jps.com.v9i3.1794
Main Article Content
Abstract
Polycystic ovary syndrome (PCOS) requires individualized pharmacotherapy because reproductive and metabolic manifestations vary among patients. This study evaluated the associations of age, documented menstrual complaints, and pregnancy-related presentations with medication-count category among patients with PCOS at Kencana Clinic, Sorong City. A retrospective cross-sectional analysis was conducted on 118 eligible records selected by computer-generated simple random sampling from 412 records dated January 2022-December 2023. Associations were analyzed using the chi-square test and expressed as odds ratios (ORs) with 95% confidence intervals (CIs). Patients aged >25 years were more likely to receive >2 medications than those aged ≤25 years (40/73 vs 16/45; OR = 2.197; 95% CI = 1.022-4.721; p = 0.042). Menstrual complaints and pregnancy-related presentations were not significantly associated with medication-count category (p = 0.297 for each comparison). Older age was associated with greater medication-count complexity, but did not establish causality. Treatment planning should integrate age with metabolic status, comorbidities, and reproductive goals.
Article Details
Section
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
How to Cite
References
Singh S, Pal N, Shubham S, Sarma DK, Verma V, Marotta F, et al. Polycystic ovary syndrome: etiology, current management, and future therapeutics. J Clin Med. 2023;12(4):1454. doi:10.3390/jcm12041454.
Salari N, Nankali A, Ghanbari A, Jafarpour S, Ghasemi H, Dokaneheifard S, et al. Global prevalence of polycystic ovary syndrome in women worldwide: a comprehensive systematic review and meta-analysis. Arch Gynecol Obstet. 2024;310(3):1303-1314. doi:10.1007/s00404-024-07607-x.
Christie, Halimah E, Yohanes DC. Review artikel: Pengaruh metformin sebagai obat off-label untuk terapi pada wanita dengan polycystic ovary syndrome (PCOS). Farmaka. 2023;21:64-77.
Kesavan S, Chaudhry GS, Akim AM, Ranneh YK. The efficacy of metformin and exenatide in polycystic ovary syndrome (PCOS) patients. Ars Pharm. 2023;64(2):100-122. doi:10.30827/ars.v64i2.27302.
Yu JH, Moon MK, Ahn HC, Yang YM. Assessing medication use patterns among patients with polycystic ovary syndrome at a tertiary care teaching hospital in South Korea: a retrospective study. Medicine (Baltimore). 2024;103(32):e39055. doi:10.1097/MD.0000000000039055.
World Health Organization. Polycystic ovary syndrome [Internet]. Geneva: World Health Organization; 2023 [cited 2026 Aug 27]. Available from: https://www.who.int/news-room/fact-sheets/detail/polycystic-ovary-syndrome.
Zeng LH, Rana S, Hussain L, Asif M, Mehmood MH, Imran I, et al. Polycystic ovary syndrome: a disorder of reproductive age, its pathogenesis, and a discussion on the emerging role of herbal remedies. Front Pharmacol. 2022;13:874914. doi:10.3389/fphar.2022.874914.
Fauser BCJM, Tarlatzis BC, Rebar RW, Legro RS, Balen AH, Lobo R, et al. Consensus on women's health aspects of polycystic ovary syndrome (PCOS). Hum Reprod. 2012;27(1):14-24. doi:10.1093/humrep/der396.
Dason ES, Koshkina O, Chan C, Sobel M. Diagnosis and management of polycystic ovarian syndrome. CMAJ. 2024;196(3):E85-E94. doi:10.1503/cmaj.231251.
Legro R. Diagnosis and treatment of polycystic ovary syndrome (PCOS): an interview with Richard Legro. BMC Med. 2015;13:64. doi:10.1186/s12916-015-0299-2.
Ratnaningsih D, Siswatibudi H, Yogi Hernawan J. Gambaran terapi penggunaan obat pada wanita usia subur dengan masalah reproduksi PCOS (polycystic ovarian syndrome) di Yogyakarta. J Permata Indones. 2022;13(2):136-144. doi:10.59737/jpi.v13i2.172.
Kujanpää L, Arffman RK, Pesonen P, Hurskainen E, Järvelin MR, Franks S, et al. Polycystic ovary syndrome presents as a multimorbid condition by age 50: birth cohort linkage to national register data. Eur J Endocrinol. 2024;190(6):409-420. doi:10.1093/ejendo/lvae057.
Teede HJ, Misso ML, Costello MF, Dokras A, Laven J, Moran LJ, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Hum Reprod. 2018;33(9):1602-1618. doi:10.1093/humrep/dey256.
Dokras A, Saini S, Gibson-Helm M, Schulkin J, Cooney LG, Teede HJ. Gaps in knowledge among physicians regarding diagnostic criteria and management of polycystic ovary syndrome. Fertil Steril. 2017;107(6):1380-1386.e1. doi:10.1016/j.fertnstert.2017.04.011.
Melo AS, Ferriani RA, Navarro PA. Treatment of infertility in women with polycystic ovary syndrome: approach to clinical practice. Clinics. 2015;70(11):765-769. doi:10.6061/clinics/2015(11)09.
Peng G, Yan Z, Liu Y, Li J, Ma J, Tong N, et al. The effects of first-line pharmacological treatments for reproductive outcomes in infertile women with PCOS: a systematic review and network meta-analysis. Reprod Biol Endocrinol. 2023;21(1):24. doi:10.1186/s12958-023-01075-9.
Teede HJ, Tay CT, Laven J, Dokras A, Moran LJ, Piltonen TT, et al. Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Fertil Steril. 2023;120(4):767-793. doi:10.1016/j.fertnstert.2023.07.025.
Strauss JF, Barbieri RL, Dokras A, Williams CJ, Williams SZ, editors. Yen & Jaffe's Reproductive Endocrinology: Physiology, Pathophysiology, and Clinical Management [Internet]. 9th ed. Philadelphia: Elsevier; 2023 [cited 2026 Aug 27]. Available from: ClinicalKey, https://www.clinicalkey.com.
Ee C, Tay CT. Pharmacological management of polycystic ovary syndrome. Aust Prescr. 2024;47(4):109-112. doi:10.18773/AUSTPRESCR.2024.030.
Melin J, Forslund M, Alesi S, Piltonen T, Romualdi D, Spritzer PM, et al. Metformin and combined oral contraceptive pills in the management of polycystic ovary syndrome: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2024;109(2):e817-e836. doi:10.1210/clinem/dgad465.
Alesi S, Forslund M, Melin J, Romualdi D, Peña A, Tay CT, et al. Efficacy and safety of anti-androgens in the management of polycystic ovary syndrome: a systematic review and meta-analysis of randomised controlled trials. EClinicalMedicine. 2023;63:102162. doi:10.1016/j.eclinm.2023.102162.
Goldberg A, Graca S, Liu J, Rao V, Witchel SF, Pena A, et al. Anti-obesity pharmacological agents for polycystic ovary syndrome: a systematic review and meta-analysis to inform the 2023 international evidence-based guideline. Obes Rev. 2024;25(5):e13704. doi:10.1111/obr.13704.
Forslund M, Melin J, Stener-Victorin E, Teede H, Vanky E, Piltonen T. International evidence-based guideline on assessment and management of PCOS: a Nordic perspective. Acta Obstet Gynecol Scand. 2024;103(1):7-12. doi:10.1111/aogs.14725.